Expansion of human cd T cells for adoptive immunotherapy using a bisphosphonate prodrug

[1]  Yoshimasa Tanaka,et al.  Live Cell Labeling with Terpyridine Derivative Proligands to Measure Cytotoxicity Mediated by Immune Cells , 2017, ChemMedChem.

[2]  Razelle Kurzrock,et al.  Hypermutated Circulating Tumor DNA: Correlation with Response to Checkpoint Inhibitor–Based Immunotherapy , 2017, Clinical Cancer Research.

[3]  P. Stephens,et al.  Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers , 2017, Molecular Cancer Therapeutics.

[4]  H. Okamura,et al.  Anti-Tumor Activity and Immunotherapeutic Potential of a Bisphosphonate Prodrug , 2017, Scientific Reports.

[5]  N. Sonenberg,et al.  Translation is actively regulated during effector CD8+ T cell differentiation , 2017, Nature Immunology.

[6]  Yoshimasa Tanaka,et al.  Enhancing adoptive cancer immunotherapy with Vγ2Vδ2 T cells through pulse zoledronate stimulation , 2017, Journal of Immunotherapy for Cancer.

[7]  H. Okamura,et al.  Targeting Cancer Cells with a Bisphosphonate Prodrug , 2016, ChemMedChem.

[8]  H. Heslop,et al.  T cells for viral infections after allogeneic hematopoietic stem cell transplant. , 2016, Blood.

[9]  S. Rosenberg,et al.  Prospects for gene-engineered T cell immunotherapy for solid cancers , 2016, Nature Medicine.

[10]  V. Nekkanti,et al.  Insoluble drug delivery strategies: review of recent advances and business prospects , 2015, Acta pharmaceutica Sinica. B.

[11]  Hong Wang,et al.  Sensor Function for Butyrophilin 3A1 in Prenyl Pyrophosphate Stimulation of Human Vγ2Vδ2 T Cells , 2015, The Journal of Immunology.

[12]  Martin L. Miller,et al.  Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer , 2015, Science.

[13]  James E. Crooks,et al.  The intracellular B30.2 domain of butyrophilin 3A1 binds phosphoantigens to mediate activation of human Vγ9Vδ2 T cells. , 2014, Immunity.

[14]  Y. Seto,et al.  Intraperitoneal injection of in vitro expanded Vγ9Vδ2 T cells together with zoledronate for the treatment of malignant ascites due to gastric cancer , 2014, Cancer medicine.

[15]  J. Nakajima,et al.  γδ T cell therapy for the treatment of non-small cell lung cancer. , 2014, Translational lung cancer research.

[16]  David T. W. Jones,et al.  Signatures of mutational processes in human cancer , 2013, Nature.

[17]  M. Distefano,et al.  Butyrophilin 3A1 Plays an Essential Role in Prenyl Pyrophosphate Stimulation of Human Vγ2Vδ2 T Cells , 2013, The Journal of Immunology.

[18]  Takuya Takahashi,et al.  Ex vivo characterization of γδ T-cell repertoire in patients after adoptive transfer of Vγ9Vδ2 T cells expressing the interleukin-2 receptor β-chain and the common γ-chain. , 2013, Cytotherapy.

[19]  E. Adams,et al.  Key implication of CD277/butyrophilin-3 (BTN3A) in cellular stress sensing by a major human γδ T-cell subset. , 2012, Blood.

[20]  F. Nestle,et al.  Xenogeneic Graft-versus-Host-Disease in NOD-scid IL-2Rγnull Mice Display a T-Effector Memory Phenotype , 2012, PloS one.

[21]  Jignasa K. Savjani,et al.  Drug Solubility: Importance and Enhancement Techniques , 2012, ISRN pharmaceutics.

[22]  C. Drake,et al.  Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. , 2012, The New England journal of medicine.

[23]  David C. Smith,et al.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.

[24]  S. Mattarollo,et al.  Clinical evaluation of autologous gamma delta T cell-based immunotherapy for metastatic solid tumours , 2011, British Journal of Cancer.

[25]  Yoshimasa Tanaka,et al.  Phase I/II study of adoptive transfer of γδ T cells in combination with zoledronic acid and IL-2 to patients with advanced renal cell carcinoma , 2011, Cancer Immunology, Immunotherapy.

[26]  E. Oldfield,et al.  Indirect Stimulation of Human Vγ2Vδ2 T Cells through Alterations in Isoprenoid Metabolism , 2011, The Journal of Immunology.

[27]  S. Takamoto,et al.  Adoptive Immunotherapy for Advanced Non-small Cell Lung Cancer Using Zoledronate-expanded &ggr;&dgr; T Cells: A Phase I Clinical Study , 2011, Journal of immunotherapy.

[28]  Yoshimasa Tanaka,et al.  Expression and function of PD‐1 in human γδ T cells that recognize phosphoantigens , 2011, European journal of immunology.

[29]  Yoshimasa Tanaka,et al.  Complete Remission of Lung Metastasis Following Adoptive Immunotherapy Using Activated Autologous γδ T-cells in a Patient with Renal Cell Carcinoma , 2010 .

[30]  Kenshi Suzuki,et al.  Clinical and immunological evaluation of zoledronate-activated Vgamma9gammadelta T-cell-based immunotherapy for patients with multiple myeloma. , 2009, Experimental hematology.

[31]  Mamoru Ito,et al.  Highly Sensitive Model for Xenogenic GVHD Using Severe Immunodeficient NOG Mice , 2009, Transplantation.

[32]  M. Rimbert,et al.  Phase-I study of Innacell γδ™, an autologous cell-therapy product highly enriched in γ9δ2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma , 2008, Cancer Immunology, Immunotherapy.

[33]  Hong Wang,et al.  Nonpeptide antigens, presentation mechanisms, and immunological memory of human Vγ2Vδ2 T cells: discriminating friend from foe through the recognition of prenyl pyrophosphate antigens , 2007, Immunological reviews.

[34]  R. Mariuzza,et al.  Conservation of Nonpeptide Antigen Recognition by Rhesus Monkey Vγ2Vδ2 T Cells1 , 2003, The Journal of Immunology.

[35]  G. De Libero,et al.  Human T Cell Receptor γδ Cells Recognize Endogenous Mevalonate Metabolites in Tumor Cells , 2003, The Journal of experimental medicine.

[36]  J. Wiesner,et al.  Identification of (E)‐4‐hydroxy‐3‐methyl‐but‐2‐enyl pyrophosphate as a major activator for human γδ T cells in Escherichia coli , 2001 .

[37]  Malcolm K. Brenner,et al.  Long–term restoration of immunity against Epstein–Barr virus infection by adoptive transfer of gene–modified virus–specific T lymphocytes , 1996, Nature Medicine.

[38]  B. Bloom,et al.  Natural and synthetic non-peptide antigens recognized by human γδ T cells , 1995, Nature.

[39]  H. Band,et al.  V gamma 2V delta 2 TCR-dependent recognition of non-peptide antigens and Daudi cells analyzed by TCR gene transfer. , 1995, Journal of immunology.

[40]  J. Wilkins,et al.  Reactivity of γδ T Cells Induced by the Tumour Cell Line RPMI 8226: Functional Heterogeneity of Clonal Populations and Role of GroEL Heat Shock Proteins , 1992, Scandinavian journal of immunology.

[41]  O. Janssen,et al.  Human cytotoxic lymphocytes. V. Frequency and specificity of gamma delta+ cytotoxic lymphocyte precursors activated by allogeneic or autologous stimulator cells. , 1990, Journal of immunology.

[42]  S. Hakomori.  A RAPID PERMETHYLATION OF GLYCOLIPID, AND POLYSACCHARIDE CATALYZED BY METHYLSULFINYL CARBANION IN DIMETHYL SULFOXIDE. , 1964, Journal of biochemistry.

[43]  M. Yamamura,et al.  Adoptive immunotherapy using autologous lymphocytes activated ex vivo with antigen stimulation for patients with incurable cancer , 2014 .

[44]  E. Adams,et al.  The Molecular Basis for Modulation of Human V9V2 T Cell Responses by CD277/Butyrophilin-3 (BTN3A)-specific , 2012 .

[45]  T. Kamigaki,et al.  Zoledronate-activated Vγ9γδ T cell-based immunotherapy is feasible and restores the impairment of γδ T cells in patients with solid tumors. , 2011, Cytotherapy.

[46]  M. Rogers,et al.  Cytosolic entry of bisphosphonate drugs requires acidification of vesicles following fluid-phase endocytosis , 2006 .

[47]  H. Spits,et al.  Functionally distinct subsets of human gamma/delta T cells. , 1991, European journal of immunology.